Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clpt.2006.08.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Increased parathyroid hormone concentration as a biomarker of atrial fibrillation in severe aortic stenosis: Editorial comment.
Kardiol Pol
January 2024
Department of Medicine (DIMED) Geriatrics Division, University of Padua, Padua, Italy.
Preoperative gastric retention in endoscopic retrograde cholangiopancreatography patients: Assessing risks and optimizing outcomes.
World J Gastrointest Surg
December 2024
Department of Gastroenterology and Hepatology/Medical Engineering Integration Laboratory of Digestive Endoscopy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
This article is a comment on the article by Jia , aiming at establishing a predictive model to predict the occurrence of preoperative gastric retention in endoscopic retrograde cholangiopancreatography preparation. We share our perspectives on this predictive model. First, further differentiation in predicting the severity of gastric retention could enhance clinical outcomes.
View Article and Find Full Text PDFUsing T-Cell Subsets to Better Characterize Immunoresiliency and Immunodeficiency in Patients with Recurrent Infections.
Infect Dis Rep
December 2024
Department of Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA.
Background/objectives: Common Variable Immunodeficiency Disease (CVID) and other immunodeficiencies can present in subtle and variable ways. Whether or not a genetic lesion can be identified, there are not well understood biomarkers that quantitatively describe how severe a deficiency is. Here we discuss two possible ranking systems, CD4/CD8 T cell ratios and Immune Health Grades, and how such data maybe applicable to some immunodeficiencies.
View Article and Find Full Text PDF[Comment on the article "Successful treatment of severe purulent peritonitis against the background of intra-abdominal hypertension syndrome"].
Khirurgiia (Mosk)
December 2024
FGAOU VO "Russian National Research University named after N.I. Pirogov". N.I. Pirogov Russian National Research University, Moscow, Russia.
Comment on the article "Successful treatment of severe purulent peritonitis against the background of intra-abdominal hypertension syndrome".
View Article and Find Full Text PDFMarstacimab: First Approval.
Drugs
December 2024
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Marstacimab (marstacimab-hncq; HYMPAVZI™) is a subcutaneously administered human monoclonal immunoglobulin G1 antibody against tissue factor pathway inhibitor (TFPI) that is being developed by Pfizer for the treatment of hemophilia A and B. Marstacimab received its first approval on 11 October 2024 in the USA. It was approved for use as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!